FrieslandCampina has announced a partnership with US-based pharmaceutical group Glycosyn to produce ingredients for the infant nutrition market.
The two have signed a technology and partnership agreement. Glycosyn has developed a patented technology for the production of oligosaccharides from lactose. FrieslandCampina’s ingredients unit, Domo, will produce and introduce these new ingredients onto the global market.
John Garrett, co-CEO, at Glycosyn, said: “Human Milk Oligosaccharides (HMO’s) are specialised carbohydrates which are naturally prevalent in mother’s milk. Through our expertise and know-how we have developed technologies which will complement FrieslandCampina’s extensive history and knowledge of infant nutrition ingredients, products and markets.”
Tine Snels, executive director of FrieslandCampina Ingredients, added: “Glycosyn helps us to take a very exciting step towards developing the next generation of infant nutrition and to strengthen our position as a market leader in infant nutrition ingredients. We are doing this to meet the growing global demand for high-quality ingredients. Our cooperation is a perfect example of co-creation. The first quantities for trials will be available in the current year.”